Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-18
2011-10-04
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
08030305
ABSTRACT:
The invention is directed to triazolopyridazine compounds of Formula I:where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
REFERENCES:
patent: 3483193 (1969-12-01), Gall et al.
patent: 3506656 (1970-04-01), Berger et al.
patent: 3823137 (1974-07-01), Berger et al.
patent: 3919200 (1975-11-01), Berger et al.
patent: 4260755 (1981-04-01), Moran et al.
patent: 4810705 (1989-03-01), Bourguignon et al.
patent: 5278161 (1994-01-01), Branca et al.
patent: 5474765 (1995-12-01), Thorpe et al.
patent: 5498774 (1996-03-01), Mitsudera et al.
patent: 5762918 (1998-06-01), Thorpe et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 6297235 (2001-10-01), Ladduwahetty et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6355798 (2002-03-01), Madin et al.
patent: 6444666 (2002-09-01), Ladduwahetty et al.
patent: 6776796 (2004-08-01), Falotico et al.
patent: 7173033 (2007-02-01), Igarashi et al.
patent: 7186720 (2007-03-01), Baroni et al.
patent: 7250518 (2007-07-01), Magee et al.
patent: 2002/0016625 (2002-02-01), Falotico et al.
patent: 2002/0111495 (2002-08-01), Magee et al.
patent: 2003/0181455 (2003-09-01), Yuan et al.
patent: 2004/0138264 (2004-07-01), Baroni et al.
patent: 2004/0147568 (2004-07-01), Yu et al.
patent: 2004/0171798 (2004-09-01), Magee et al.
patent: 2004/0192696 (2004-09-01), Green et al.
patent: 2005/0096322 (2005-05-01), Igarashi et al.
patent: 2005/0261297 (2005-11-01), Igarashi et al.
patent: 2006/0173009 (2006-08-01), Kanoh et al.
patent: 2158994 (1994-09-01), None
patent: 2132489 (1995-03-01), None
patent: 1545598 (1969-11-01), None
patent: 1670160 (1970-11-01), None
patent: 2030581 (1971-12-01), None
patent: 2113438 (1972-09-01), None
patent: 2147013 (1973-03-01), None
patent: 2161587 (1973-06-01), None
patent: 2222834 (1973-11-01), None
patent: 4309285 (1994-09-01), None
patent: 156734 (1985-10-01), None
patent: 156734 (1986-12-01), None
patent: 404190 (1990-12-01), None
patent: 464572 (1992-01-01), None
patent: 464572 (1992-10-01), None
patent: 404190 (1995-10-01), None
patent: 1229034 (2002-08-01), None
patent: 1481977 (2004-12-01), None
patent: 1324060 (1971-12-01), None
patent: 63199347 (1988-08-01), None
patent: 63310891 (1988-12-01), None
patent: WO 9421616 (1994-09-01), None
patent: WO 9632907 (1996-10-01), None
patent: WO 9937303 (1999-07-01), None
patent: WO 0006566 (2000-02-01), None
patent: WO 0134603 (2001-05-01), None
patent: WO 0134603 (2002-01-01), None
patent: WO 0212236 (2002-02-01), None
patent: WO 02085888 (2002-10-01), None
patent: WO 03032916 (2003-04-01), None
patent: WO 03074525 (2003-09-01), None
patent: WO 03032916 (2004-03-01), None
patent: WO 2004017950 (2004-03-01), None
patent: WO 2004021984 (2004-03-01), None
patent: WO 2004021984 (2004-03-01), None
patent: WO 2004017950 (2004-05-01), None
patent: WO 2004058769 (2004-07-01), None
patent: WO 2004058769 (2004-09-01), None
patent: WO 2005/002590 (2005-01-01), None
patent: WO 2005004607 (2005-01-01), None
patent: WO 2005004808 (2005-01-01), None
patent: WO 2005010005 (2005-02-01), None
patent: WO 2006/135667 (2006-12-01), None
patent: WO 2007064797 (2007-06-01), None
patent: WO 2007/138472 (2007-12-01), None
patent: WO 2008/008539 (2008-01-01), None
Albright, J.D. et al., “Synthesis and Anxiolytic Activity of 6-(Substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines”, Journal of Medicinal Chemistry, 1981, vol. 24, No. 5, pp. 592-600.
Amer, Adel et al., “Dehydration of 2-(2-Arylethyl)-2-hydroxy-4-oxopentanoic Acids and Their Hydrazones to Form Heterocycles [1]”, Journal fur praktische Chemie Chemiker-Zeitung, 339, 1997, pp. 20-25.
Bieche, Ivan et al., Infrequent mutations of theMETgene in spordic breast tumours, Int. J. Cancer: vol. 82, pp. 908-910, 1999.
Bratusek, Urska et al., “Synthesis and Reactivity of (Z)-3-Benzoylamino-4-Dimethylamino-2-OXYO-3-Butene, Preparation of 1-Aryl- and 1-Heteroaryl-substituted 4-Benzoylamino-5-Methyl-1H-Pyrazoles”, Heerocycles, vol. 57, No. 11, 2002, pp. 2045-2064.
Bratusek, Urska, “Transformation of 4-(1-Dimethylaminoethylidene)-2-phenyl-5(4H)-oxazolone into Methyl 2-Benzoylamino-3-oxobutanoate. The Synthesis of 1-Substituted 4-Benzoylamino-3-methyl-5(2H)-pyrazolones”, J. Heterocyclic Chem., vol. 35, pp. 1281-1284, 1998.
Vinot, Nicole et al., “Etude de l'acide y-benzimidazobutyrique”, Laboratoire de Chimie Organique II, Faculte des Sciences, vol. 45, pp. 245-247 (Please advise applicant f translation should be provided), 1963.
Camp, Robert L. et al., “Met Expression Is Associated with Poor Outcome in Patients with Axillary Lymph Node Negative Breast Carcinoma”, American Cancer Society, Dec. 1, 1999, vol. 86, No. 11, pp. 2259-2265.
Kirmse, Wolfgang et al., “Zerfall von 1-Arylcyclopropandiazonium-lonen”, Chem. Ber. 119, 1986, pp. 3693-3703 (Please advise if translation should be provided).
Bratusek, Urska et al., “The synthesis of N-phthaloyl-azatryptophan derivatives,” Acta Chimica Slovenica (1996), 43(2), 105-117.
Cucek, Karmen et al., “Synthesis of novel [1,2,4]triazolo[4,3-b]pyridazines”, Faculty of Chemistry and Chemical Technology, University of Ljubljana, Askerceva 5, 1000, Ljubljana, Arkivoc, 2001, pp. 79-86.
Di Renzo, M.F. et al., “Overexpression of the c-MET/HGFreceptor in human thyroid carcinomas derived from the follicular epithelium”, J. Endocrinol. Invest. vol. 18: 1995, pp. 134-139.
Di Renzo, M.F. et al., “Overexpression of theMET/HGFReceptor in Ovarian Cancer”, Int. J. Cancer: vol. 58, 1994, pp. 658-662.
Di Renzo, M.F. et al., “Somatic mutations of the MET oncogene are selected during metastic spread of human HNSC carcinomas”, Oncogene, vol. 19, 2000, pp. 1547-1555.
Ebert, Matthias et al., “Coexpression of the c-met Proto-oncogene and Hepatocyte Growth Factor in Human Pancreatic Cancer1”, Cancer Research, vol. 54, Nov. 15, 1994, pp. 4775-5778.
Massry, Abdel Moneim El et al., “Synthesis of New s-Triazolo[4,3-b]Pyridazines”, Heterocycles, vol. 29, No. 10, 1989, pp. 1907-1914.
Ferracini, Riccardo et al., “The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit”, Oncogene, vol. 10, 1995, pp. 739-749.
Fischer, Joachim et al., “Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours”, Oncogene, vol. 17, 1998, pp. 733-739.
Gohji, Kazuo et al., “Independent Prognostic Value of Serum hepatocyte Growth Factor in Bladder Cancer”, Journal of Clinical Oncology, vol. 18, No. 16, Aug. 2000, pp. 2963-2971.
Kuniyasu, Hiroki, et al., “Frequent amplification of the c-met gene in scirrhous type stomach cancer*”, Biochemical and Biophysical Research Communications, vol. 189, No. 1, Nov. 30, 1992, pp. 227-232.
Hansel, Donna E., et al., “Met Proto-Oncogene and Insulin-Like Growth Factor Binding Protein 3 Overexpression Correlates with Metastic Ability in Well-Differentiated Pancreatic Endocrine Neoplasms”, Clinical Cancer Research, vol. 10, Sep. 15, 2004, pp. 6152-6158.
Hellstrom, Karl Erik et al., “Antibodies for Drug Delivery”Oncogen, pp. 623-653, 1987.
Herrera, Luis J. et al., “The HGF Receptor c-Met is Overexpressed in Esophageal Adenocarcinoma”, Neoplasia, vol. 7, No. 1, Jan. 2005, pp. 75-84.
He Yuedong, Peng Z, Pan X, Wang H,
Alexander Richard
Connors Richard W.
Cummings Maxwell D.
Galemmo Robert A.
Hufnagel Heather Rae
Jaisle Cecilia M
Janssen Pharmaceutica N.V.
Shah Rajiv S.
Wilson James O
LandOfFree
Triazolopyridazines as kinase modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolopyridazines as kinase modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolopyridazines as kinase modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252803